Viewing Study NCT01630018


Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2025-12-26 @ 4:05 AM
Study NCT ID: NCT01630018
Status: COMPLETED
Last Update Posted: 2016-09-22
First Post: 2012-03-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
Sponsor: Chong Kun Dang Pharmaceutical
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module